David R. FitzPatrick

David R. FitzPatrick

Auto-generated profile, based on publicly available information

David R. FitzPatrick

MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2015 in Nature
Verified
Journal Article
Open access
PDF file
TCThe UK10K Consortium
The UK10K Consortium
WGWriting group
Writing group
KWKlaudia Walter
Klaudia Walter
JMJosine L. Min
Josine L. Min
JHJie Huang
Jie Huang
WZWeihua Zhang
Weihua Zhang
The contribution of rare and low-frequency variants to human traits is largely unexplored. Here we describe insights from sequencing whole genomes (low read depth, 7×) or exomes (high read depth, 80×) of nearly 10,000 individuals from population-based and disease collections. In extensively phenotyped cohorts we characterize over 24 million novel sequence variants, generate a highly accurate imputation reference panel and identify novel alleles associated with levels of triglycerides (APOB), adiponectin (ADIPOQ) and low-density lipoprotein cholesterol (LDLR and RGAG1) from single-marker and rare variant aggregation tests. We describe population structure and functional annotation of rare and low-frequency variants, use the data to estimate the benefits of sequencing for association studies, and summarize lessons from disease-specific collections. Finally, we make available an extensive resource, including individual-level genetic and phenotypic data and web-based tools to facilitate the exploration of association results.

11 November 2013 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
SKSebastian Köhler
Sebastian Köhler
SDSandra C. Doelken
Sandra C. Doelken
CMChristopher J. Mungall
Christopher J. Mungall
SBSebastian Bauer
Sebastian Bauer
HFHelen V. Firth
Helen V. Firth
PRPeter N. Robinson
Peter N. Robinson
The Human Phenotype Ontology (HPO) project, available at http://www.human-phenotype-ontology.org, provides a structured, comprehensive and well-defined set of 10,088 classes (terms) describing human phenotypic abnormalities and 13,326 subclass relations between the HPO classes. In addition we have developed logical definitions for 46% of all HPO classes using terms from ontologies for anatomy, cell types, function, embryology, pathology and other domains. This allows interoperability with several resources, especially those containing phenotype information on model organisms such as mouse and zebrafish. Here we describe the updated HPO database, which provides annotations of 7,278 human hereditary syndromes listed in OMIM, Orphanet and DECIPHER to classes of the HPO. Various meta-attributes such as frequency, references and negations are associated with each annotation. Several large-scale projects worldwide utilize the HPO for describing phenotype information in their datasets. We have therefore generated equivalence mappings to other phenotype vocabularies such as LDDB, Orphanet, MedDRA, UMLS and phenoDB, allowing integration of existing datasets and interoperability with multiple biomedical resources. We have created various ways to access the HPO database content using flat files, a MySQL database, and Web-based tools. All data and documentation on the HPO project can be found online.

1 April 2015 in The Lancet
Verified
Journal Article
Open access
CWCaroline F Wright
Caroline F Wright
TFTomas W Fitzgerald
Tomas W Fitzgerald
WJWendy D Jones
Wendy D Jones
SCStephen Clayton
Stephen Clayton
JMJeremy F McRae
Jeremy F McRae
HFHelen V Firth
Helen V Firth
Human genome sequencing has transformed our understanding of genomic variation and its relevance to health and disease, and is now starting to enter clinical practice for the diagnosis of rare diseases. The question of whether and how some categories of genomic findings should be shared with individual research participants is currently a topic of international debate, and development of robust analytical workflows to identify and communicate clinically relevant variants is paramount. The Deciphering Developmental Disorders (DDD) study has developed a UK-wide patient recruitment network involving over 180 clinicians across all 24 regional genetics services, and has performed genome-wide microarray and whole exome sequencing on children with undiagnosed developmental disorders and their parents. After data analysis, pertinent genomic variants were returned to individual research participants via their local clinical genetics team. Around 80,000 genomic variants were identified from exome sequencing and microarray analysis in each individual, of which on average 400 were rare and predicted to be protein altering. By focusing only on de novo and segregating variants in known developmental disorder genes, we achieved a diagnostic yield of 27% among 1133 previously investigated yet undiagnosed children with developmental disorders, whilst minimising incidental findings. In families with developmentally normal parents, whole exome sequencing of the child and both parents resulted in a 10-fold reduction in the number of potential causal variants that needed clinical evaluation compared to sequencing only the child. Most diagnostic variants identified in known genes were novel and not present in current databases of known disease variation. Implementation of a robust translational genomics workflow is achievable within a large-scale rare disease research study to allow feedback of potentially diagnostic findings to clinicians and research participants. Systematic recording of relevant clinical data, curation of a gene-phenotype knowledge base, and development of clinical decision support software are needed in addition to automated exclusion of almost all variants, which is crucial for scalable prioritisation and review of possible diagnostic variants. However, the resource requirements of development and maintenance of a clinical reporting system within a research setting are substantial. Health Innovation Challenge Fund, a parallel funding partnership between the Wellcome Trust and the UK Department of Health.

5 February 2018 in Nature Reviews Genetics
Verified
Journal Article
Closed access
PDF file
CWCaroline F. Wright
Caroline F. Wright
DFDavid R. FitzPatrick
David R. FitzPatrick
HFHelen V. Firth
Helen V. Firth

10 October 2004 in Nature Genetics
Verified
Journal Article
Closed access
SHSandra Hanks
Sandra Hanks
KCKim Coleman
Kim Coleman
SRSarah Reid
Sarah Reid
APAlberto Plaja
Alberto Plaja
HFHelen Firth
Helen Firth
NRNazneen Rahman
Nazneen Rahman

3 March 2003 in Nature Genetics
Verified
Journal Article
Open access
PDF file
JFJudy Fantes
Judy Fantes
NRNicola K. Ragge
Nicola K. Ragge
SLSally-Ann Lynch
Sally-Ann Lynch
NMNiolette I. McGill
Niolette I. McGill
JCJ. Richard O. Collin
J. Richard O. Collin
DFDavid R. FitzPatrick
David R. FitzPatrick
A submicroscopic deletion containing SOX2 was identified at the 3q breakpoint in a child with t(3;11)(q26.3;p11.2) associated with bilateral anophthalmia. Subsequent SOX2 mutation analysis identified de novo truncating mutations of SOX2 in 4 of 35 (11%) individuals with anophthalmia. Both eyes were affected in all cases with an identified mutation.